KITRON And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) – KITRON (KIT.OL), NEOEN (NEOEN.PA), RYANAIR HOLD. PLC (RYA.IR) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. KITRON (KIT.OL)

1046.9% sales growth and 22.67% return on equity

Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China, Malaysia, and the United States. It manufactures and sells electronics that are embedded in the customer's own products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high-level assembly lines, and environmental durability testing. Its services comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance, as well as logistics and distribution, and product deployment services. The company markets its services to connectivity, electrification, industry, medical devices, and defence/aerospace sectors. Kitron ASA was incorporated in 1996 and is headquartered in Billingstad, Norway.

Earnings Per Share

As for profitability, KITRON has a trailing twelve months EPS of kr2.23.

PE Ratio

KITRON has a trailing twelve months price to earnings ratio of 12.83. Meaning, the purchaser of the share is investing kr12.83 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.67%.

Moving Average

KITRON’s value is way below its 50-day moving average of kr34.85 and way below its 200-day moving average of kr33.23.

Volume

Today’s last reported volume for KITRON is 535373 which is 14.47% above its average volume of 467685.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 860% and 1100%, respectively.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Apr 26, 2024, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 2.45%.

More news about KITRON.

2. NEOEN (NEOEN.PA)

48.5% sales growth and 3.27% return on equity

Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, NEOEN has a trailing twelve months EPS of €0.94.

PE Ratio

NEOEN has a trailing twelve months price to earnings ratio of 27.91. Meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.27%.

Sales Growth

NEOEN’s sales growth is 63.4% for the ongoing quarter and 48.5% for the next.

Yearly Top and Bottom Value

NEOEN’s stock is valued at €26.24 at 02:20 EST, way below its 52-week high of €38.94 and way above its 52-week low of €21.80.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 20, 2024, the estimated forward annual dividend rate is 0.15 and the estimated forward annual dividend yield is 0.39%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.7%, now sitting on 503.1M for the twelve trailing months.

More news about NEOEN.

3. RYANAIR HOLD. PLC (RYA.IR)

38.7% sales growth and 23.1% return on equity

Ryanair Holdings plc, together with its subsidiaries, provides scheduled-passenger airline services in Ireland, the United Kingdom, Spain, Italy, and internationally. The company is also involved in the provision of various ancillary services, such as non-flight scheduled and Internet-related services, as well as in-flight sale of beverages, food, duty-free, and merchandise; and markets car hire, travel insurance, and accommodation services through its website and mobile app. Furter, it offers aircraft and passenger handling, ticketing, and maintenance and repair services; and markets car parking, fast-track, airport transfers, attractions, and activities on its website and mobile app, as well as sells gift vouchers. The company was incorporated in 1996 and is headquartered in Swords, Ireland.

Earnings Per Share

As for profitability, RYANAIR HOLD. PLC has a trailing twelve months EPS of €1.41.

PE Ratio

RYANAIR HOLD. PLC has a trailing twelve months price to earnings ratio of 11.86. Meaning, the purchaser of the share is investing €11.86 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.1%.

More news about RYANAIR HOLD. PLC.

4. J.MARTINS,SGPS (JMT.LS)

17.7% sales growth and 28.68% return on equity

Jerónimo Martins, SGPS, S.A. operates in the food distribution and specialized retail sectors in Portugal, Poland, and Colombia. The company operates through Portugal Retail; Portugal Cash & Carry; Poland Retail; Colombia Retail; and Others, Eliminations and Adjustments segments. It operates food stores under the Biedronka name; and a chain of health and beauty stores under the Hebe banner in Poland, as well as food stores under the Ara name in Colombia. The company also operates supermarkets under the Pingo Doce banner; and cash and carry stores under the Recheio name in Portugal, and under the Bodega del Canasto name in Colombia. In addition, it operates restaurants under the Pingo Doce name; para-pharmacies and petrol stations under Bem-Estar brand; and clothing under Code brand. Further, the company operates coffee shops and kiosks under the Jeronymo name; and chocolates and confectionary retail stores under Hussel name. Additionally, the company engages in human resources top management, real estate management and administration, training, and saline brackish waters aquaculture; wholesale of fruit and vegetables; retail management, consultancy, and logistics activities; purchase and sale of real estate; growing of crops and farming of animals; retail sale of health and beauty products; manufacture of milk and dairy products; rental of air transport equipment; and provision of business portfolio management, financial, and sea passenger water transport services. It is also involved in the trading and distribution of consumer goods; retail and wholesale of non-food products; other business support service activities; and provision of services in the area of wholesale and retail distribution. The company was founded in 1792 and is headquartered in Lisbon, Portugal. Jerónimo Martins, SGPS, S.A. operates as a subsidiary of Sociedade Francisco Manuel Dos Santos, S.G.P.S., S.A.

Earnings Per Share

As for profitability, J.MARTINS,SGPS has a trailing twelve months EPS of €1.04.

PE Ratio

J.MARTINS,SGPS has a trailing twelve months price to earnings ratio of 17. Meaning, the purchaser of the share is investing €17 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.68%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 13.8% and 29.6%, respectively.

Sales Growth

J.MARTINS,SGPS’s sales growth is 20.1% for the current quarter and 17.7% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 21%, now sitting on 28.01B for the twelve trailing months.

More news about J.MARTINS,SGPS.

5. SANOFI (SAN.PA)

7.4% sales growth and 5.82% return on equity

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Earnings Per Share

As for profitability, SANOFI has a trailing twelve months EPS of €4.3.

PE Ratio

SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 47.08B for the twelve trailing months.

Volume

Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.

More news about SANOFI.

6. VISTIN PHARMA (VISTN.OL)

6.6% sales growth and 23.89% return on equity

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 18.12. Meaning, the purchaser of the share is investing kr18.12 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Nov 6, 2024, the estimated forward annual dividend rate is 1.75 and the estimated forward annual dividend yield is 6.27%.

More news about VISTIN PHARMA.

7. CREDIT AGRICOLE (ACA.PA)

6.1% sales growth and 7.17% return on equity

Crédit Agricole S.A. provides retail, corporate, insurance, and investment banking products and services in France and internationally. It operates through French Retail Banking – Regional Banks; French Retail Banking – LCL; International Retail Banking; Asset Gathering; Large Customers; and Specialised Financial Services segments. The company offers banking products and services, finance, savings, wealth management, payment, and cash flow management services; consumer finance products; savings/retirement, death and disability/creditor/group, and property and casualty insurance products; investment solutions; and banking and specialized financial services. It also provides investment banking, structured finance, international trade finance, commercial banking, capital market, and syndication services; financing solutions for property and equipment investment and renewal requirements; trade receivable financing and management solutions for corporates; asset servicing solutions for investment products, as well as various asset classes, such as execution, clearing, forex, security lending and borrowing, custody, depositary bank, fund administration, middle-office outsourcing solutions, and fund distribution support and issuer services; and online banking services. The company serves retail customers, corporates, banks and financial institutions, government agencies, and local authorities. Crédit Agricole S.A. was founded in 1894 and is headquartered in Montrouge, France. Crédit Agricole S.A. operates as a subsidiary of SAS Rue La Boetie.

Earnings Per Share

As for profitability, CREDIT AGRICOLE has a trailing twelve months EPS of €1.94.

PE Ratio

CREDIT AGRICOLE has a trailing twelve months price to earnings ratio of 7.12. Meaning, the purchaser of the share is investing €7.12 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.17%.

More news about CREDIT AGRICOLE.

Leave a Reply

Your email address will not be published. Required fields are marked *